Seeking Alpha

StemCells (STEM) +23% after announcing the results of preclinical trials which showed that...

StemCells (STEM) +23% after announcing the results of preclinical trials which showed that transplanting its proprietary human neural stem cells "restored memory and enhanced synaptic function in two animal models relevant to Alzheimer's disease." The data was presented at the Alzheimer's Association International Conference (AAIC 2012). (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs